Plain-English translation of NCT05053607 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is designed to understand what it's really like for patients with relapsed or refractory multiple myeloma to receive isatuximab as their treatment. Researchers want to learn about your treatment experience — including how the medication affects your daily life, side effects, quality of life, and financial concerns — by collecting both your feedback and data from a wearable activity tracker you'll wear.
While isatuximab is a standard treatment for this type of blood cancer, researchers don't have enough real-world information about how patients actually experience the medication day-to-day. This study fills that gap by listening directly to patients about their struggles, successes, and quality of life during treatment.
You likely qualify if…
You likely don't qualify if…
You will enroll in a 3-month digital health coaching program where you'll wear a Fitbit device to track your daily physical activity and complete surveys and questionnaires about your treatment experience, quality of life, symptom burden, and financial concerns. You'll communicate with the study team through text messages, emails, and a mobile app. Optionally, you may also participate in one interview where you can talk in detail about your treatment experience.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States